151 related articles for article (PubMed ID: 32675466)
1. Atypical Painful Purpuric Cutaneous Nodules With Ibrutinib.
Marcaillou M; Stéphanie D; Marion B; Julien S; Christophe B
Am J Dermatopathol; 2020 Dec; 42(12):1012-1014. PubMed ID: 32675466
[No Abstract] [Full Text] [Related]
2. Rituximab-induced vasculitis.
Dereure O; Navarro R; Rossi JF; Guilhou JJ
Dermatology; 2001; 203(1):83-4. PubMed ID: 11549810
[No Abstract] [Full Text] [Related]
3. Bortezomib-associated cutaneous vasculitis.
Garcia-Navarro X; Puig L; Fernández-Figueras MT; Dalmau J; Roe E; Alomar A
Br J Dermatol; 2007 Oct; 157(4):799-801. PubMed ID: 17635511
[No Abstract] [Full Text] [Related]
4. Early morphea during treatment with ibrutinib in a patient with chronic lymphocytic leukemia.
Ozbagcivan O; Akarsu S; Nazli EC; Lebe B; Fetil E
Ann Hematol; 2021 Jan; 100(1):293-294. PubMed ID: 32221651
[No Abstract] [Full Text] [Related]
5. Injection site vasculitis in a patient receiving interferon alfa for chronic hepatitis C.
Christian MM; Diven DG; Sanchez RL; Soloway RD
J Am Acad Dermatol; 1997 Jul; 37(1):118-20. PubMed ID: 9216535
[No Abstract] [Full Text] [Related]
6. Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.
İskender G; İskender D; Ertek M
Turk J Haematol; 2020 Aug; 37(3):208-209. PubMed ID: 32248674
[No Abstract] [Full Text] [Related]
7. Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.
Molica S; Baumann T; Giannarelli D
Eur J Haematol; 2021 Mar; 106(3):425-427. PubMed ID: 33190324
[No Abstract] [Full Text] [Related]
8. Ibrutinib skin toxicities: Report of two cases.
Bloomquist MS; Curry JL; Krishnan B; Rivero G; Curry CV; Diwan AH
J Cutan Pathol; 2022 Apr; 49(4):363-368. PubMed ID: 34726785
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib-Associated Leukocytoclastic Vasculitis in a Patient with Chronic Lymphocytic Leukemia.
Kaya A; Aras İ; Özkan Kurtgöz P; Çakıroğlu U
Turk J Haematol; 2024 Mar; 41(1):57-58. PubMed ID: 38433497
[No Abstract] [Full Text] [Related]
10. Overall survival benefit of symptom monitoring in real-world patients with chronic lymphocytic leukaemia treated with ibrutinib: a FiLO group study.
Ysebaert L; Quinquenel A; Bijou F; Ferrant E; Michallet AS;
Eur J Cancer; 2020 Aug; 135():170-172. PubMed ID: 32585590
[No Abstract] [Full Text] [Related]
11. An oral drug for chronic lymphocytic leukemia.
Koehler A
JAAPA; 2020 Feb; 33(2):51-53. PubMed ID: 31990837
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib-Induced Neutrophilic Dermatosis.
El Halabi L; Cherif-Rebai K; Michot JM; Ghez D
Am J Dermatopathol; 2018 Mar; 40(3):198-200. PubMed ID: 29473834
[TBL] [Abstract][Full Text] [Related]
13. [Severe systemic vasculitis induced by ibrutinib].
Fenot M; Woaye Hune P; Vigouroux S; Veyrac G; Poiraud C
Rev Med Interne; 2024 Jan; 45(1):13-16. PubMed ID: 37951781
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous vasculitis associated with rofecoxib.
Lillicrap MS; Merry P
Rheumatology (Oxford); 2003 Oct; 42(10):1267-8. PubMed ID: 14508048
[No Abstract] [Full Text] [Related]
15. Cutaneous vasculitis developed in a patient with breast cancer undergoing aromatase inhibitor treatment.
Shoda H; Inokuma S; Yajima N; Tanaka Y; Setoguchi K
Ann Rheum Dis; 2005 Apr; 64(4):651-2. PubMed ID: 15769928
[No Abstract] [Full Text] [Related]
16. Necrotizing vasculitis due to gefitinib (Iressa).
Fernández-Guarino M; Ryan AM; Pérez-García B; Gónzalez-López C; Olasolo PJ
Int J Dermatol; 2007 Aug; 46(8):890-1. PubMed ID: 17651185
[No Abstract] [Full Text] [Related]
17. Leflunomide induced vasculitis--a dose-response relationship.
Chan AT; Bradlow A; McNally J
Rheumatology (Oxford); 2003 Mar; 42(3):492-3. PubMed ID: 12626811
[No Abstract] [Full Text] [Related]
18. Adalimumab causing vasculitis.
Orpin SD; Majmudar VB; Soon C; Azam NA; Salim A
Br J Dermatol; 2006 May; 154(5):998-9. PubMed ID: 16634911
[No Abstract] [Full Text] [Related]
19. Cutaneous, Purpuric Painful Nodules Upon Addition of Ibrutinib to RCVP Therapy in a CLL Patient: A Distinctive Reaction Pattern Reflecting Iatrogenic Th2 to Th1 Milieu Reversal.
Mulvey JJ; Nuovo GJ; Magro CM
Am J Dermatopathol; 2016 Jul; 38(7):492-8. PubMed ID: 27043332
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib-Induced Skin Rash.
Kirar S; Gogia A; Gupta R; Mallick S
Turk J Haematol; 2021 Feb; 38(1):81-83. PubMed ID: 33053966
[No Abstract] [Full Text] [Related]
[Next] [New Search]
